검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% |
|---|---|
Overview Program | Fluorouracil |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Muscle Invasive Bladder Carcinoma |
Overview Indication | Advanced or Metastatic Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway |
MoA Biomarker | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | thrombocytopenia, inflammation of the esophagus, stomach, and small bowel |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical Result source | ClinicalTrials.gov NCT04430738 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% |
|---|---|
Overview Program | Fluorouracil |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Muscle Invasive Bladder Carcinoma |
Overview Indication | Advanced or Metastatic Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway |
MoA Biomarker | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | thrombocytopenia, inflammation of the esophagus, stomach, and small bowel |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical Result source | ClinicalTrials.gov NCT04430738 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교